Next Article in Journal
Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years
Previous Article in Journal
Platelet Rich Plasma as a Potential Therapy for Chronic Toxoplasmosis in Immunocompetent and Immunocompromised Murine Model
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis

by
Abdulaziz F. Alhussaini
1,
Mahmoud Elshal
1,2,* and
Sara H. Hazem
1
1
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, ElGomhoria Street, Mansoura 35516, Egypt
2
AlGhad College for Applied Medical Sciences, Najran 66243, Saudi Arabia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2026, 19(6), 909; https://doi.org/10.3390/ph19060909
Submission received: 15 April 2026 / Revised: 21 May 2026 / Accepted: 28 May 2026 / Published: 8 June 2026
(This article belongs to the Section Pharmacology)

Abstract

Background/Objectives: Abrupt impairment of liver functions, extensive hepatocellular necrosis, and high short-term mortality in patients without pre-existing liver disease are characteristic hallmarks of acute liver failure (ALF). Therapeutic options for ALF remain extremely limited, with liver transplantation representing the only definitive intervention in advanced cases, highlighting the urgent need for effective pharmacological strategies to limit early hepatic injury and disease progression. Honokiol (HON), a biphenolic lignan derived from Magnolia species, possesses documented antioxidant and anti-inflammatory properties; however, its protective potential and mechanisms in ALF remain incompletely defined. Methods: A lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced ALF murine model was employed to explore the hepatoprotective potential of HON (5 and 10 mg/kg) and its possible underlying mechanisms. Results: HON pretreatment significantly (i) attenuated hepatocellular injury, as evidenced by marked reductions in serum liver enzyme levels and suppression of necroinflammation and neutrophil infiltration. HON also (ii) restored hepatic redox homeostasis by enhancing antioxidant defenses and reducing lipid peroxidation and nitrosative stress. These effects were accompanied by (iii) activation of the Keap1/Nrf2/HO-1 signaling axis; (iv) suppression of NF-κB activation with subsequent inhibition of NLRP3 inflammasome and caspase-1 activation; and (v) reduction in hepatic TNF-α, IL-1β, and IL-18 levels. In parallel, HON (vi) restored mitochondrial SIRT3 and AMPK signaling. Conclusions: Our findings demonstrate that HON effectively protects against LPS/D-GalN-induced ALF via coordinated enhancement of antioxidant defense and suppression of inflammatory signaling pathways, supporting its potential as a promising pleiotropic therapeutic candidate for ALF.
Keywords: honokiol; hepatoprotection; acute liver failure; LPS/D-galactosamine; oxidative stress; inflammation honokiol; hepatoprotection; acute liver failure; LPS/D-galactosamine; oxidative stress; inflammation
Graphical Abstract

Share and Cite

MDPI and ACS Style

Alhussaini, A.F.; Elshal, M.; Hazem, S.H. Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis. Pharmaceuticals 2026, 19, 909. https://doi.org/10.3390/ph19060909

AMA Style

Alhussaini AF, Elshal M, Hazem SH. Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis. Pharmaceuticals. 2026; 19(6):909. https://doi.org/10.3390/ph19060909

Chicago/Turabian Style

Alhussaini, Abdulaziz F., Mahmoud Elshal, and Sara H. Hazem. 2026. "Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis" Pharmaceuticals 19, no. 6: 909. https://doi.org/10.3390/ph19060909

APA Style

Alhussaini, A. F., Elshal, M., & Hazem, S. H. (2026). Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis. Pharmaceuticals, 19(6), 909. https://doi.org/10.3390/ph19060909

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop